Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Studies in Theoretical Biology: A Collectionof Undergraduate Research

120 pages, 7 articles*Studies in Theoretical Biology: A Collectionof Undergraduate Research* (Castillo-Chavez, Carlos) 120 pages*A Model Describing the Response of the Immune System to Mycobacterium tuberculosis* (Herrera, Christian; Lima, Sharon; Munoz, Roberto; Ramos, Gloria; Rodriguez, Ariel; Salzberg, Claudia) 19 pages*Mathematical Models to Study the Outbreaks of Ebola* (Astacio, Jaime; Briere, DelMar; Guillen, Milton; Martinez, Josue; Rodriguez, Francisco; Valenzuela-Campos, Noe) 18 pages*Stochastic Simulations of a Spatial SIR Model* (Camacho, Judit; Carreon, Fernando; Castillo-Guajardo, Derik; Jimenez-Perez, Hugo; Montoya-Gallardo, Leticia; Saenz, Ricardo A.) 14 pages*HIV-1 Replication Rate* (Arias, Michelle J.; Inguez, Delmy; Camacho, Erika T.; Castillo, Rafael B.; Melon, Eliel; Parra, Luz E.) 20 pages*The Effects of Vaccination in a Core Group* (Bobadilla, Marina; Lozano, Sharon Ann; Maia, Jessica Mendes; Villarreal, Julio Casar; Wilson, Novaline Dawn; Winston, Roberta) 19 pages*A Mathematical Model of the Dynamics of Rickettsia rickettsii in Tick-Host Interaction* (Alderete, Mary E.; Castillo-Garsow, Carlos W.; Salivia, Guarionex Jordan; Lara-Moreno, Carlos F.; Ramirez, Gina F.; Yichoy, Monica F.) 18 page

Clínica Integral I - OD536 - 202102

Descripción: El curso de Clínica Integral 1 es un curso teórico - práctico de modalidad blended que pertenece a la línea 1Educación Clínica y Profesional de la carrera de Odontología, dirigido a estudiantes del quinto nivel y tiene como requisito el curso OD168 Práctica Preclínica Odontológica 1 y OD476 Integración Clínica Patológica 1. Este curso permitirá a los estudiantes integrar los conocimientos teóricos y habilidades que le permitan desarrollar competencias clínicas para el diagnóstico y ejecución de diversos tratamientos, con el fin de prevenir y/o restablecer la salud oral de manera interdisciplinaria. Propósito: El curso de Clínica Integral 1 ha sido diseñado con el propósito de desarrollar las competencias generales de: Comunicación oral, Comunicación escrita, Pensamiento crítico y Manejo de información en su nivel 2. Y las competencias específicas de: Práctica Clínica y Profesionalismo en su nivel 2

Internado Clínico - OD540 - 202101

Descripción: Internado Clínico es un curso Blended que cuenta con 12 horas de taller presencial dedicadas al trabajo clínico dentro del Centro Universitario de Salud y 2 horas de taller virtual sincrónicas donde desarrollarán habilidades interprofesionales; teniendo como requisito el curso OD539 Clínica Integral 4 y se dicta en simultáneo con el curso OD326 Seminario Integrador I. 1El presente curso permite a los estudiantes demostrar las competencias clínicas propias de un odontólogo profesional, con sentido ético y responsabilidad, para realizar el correcto diagnóstico de los pacientes, identificando los determinantes de riesgos de enfermedad del individuo y asociarlos a un contexto clínico y familiar. De esta forma, el estudiante podrá plantear estrategias terapéuticas y preventivas consensuadas con los pacientes gracias a una comunicación oral efectiva y empática. Propósito: El curso ha sido diseñado de tal forma que el estudiante pueda demostrar no solo habilidades clínicas a través de requisitos procedimentales, sino también, su capacidad para trabajar en equipo interprofesional que le permitan satisfacer las demandas cada vez más complejas del entorno actual de atención en salud. El curso contribuye directamente al desarrollo de las competencias generales de Comunicación Oral en el nivel 3 y las competencias específicas de: Práctica Clínica- Diagnóstico , Práctica Clínica-Tratamiento , Práctica Clínica-Prevención y Profesionalismo-Sentido Ético y Legal y Responsabilidad Profesional en su nivel 3

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk